Jaskirat Sethi

Assistant Professor

UAMS

Also affiliated: University of Arkansas Medical Center (2022)

Internal Medicine, College of Medicine

4 h-index 13 pubs 62 cited

Research Areas

Biomedical Subjects

Links

Lab Website UAMS TRI Profile

OverviewAI-generated summary

Jaskirat Sethi's research focuses on the clinical outcomes and management of patients with relapsed refractory multiple myeloma. Sethi has investigated the feasibility of outpatient stem cell transplantation for multiple myeloma patients and identified risk factors predictive of hospital admission. Further work has examined the characteristics and prognostic factors for patients with multiple myeloma admitted to the intensive care unit, providing insights into disease progression and patient care needs. Sethi's publications also address specific treatment toxicities, such as corneal toxicity associated with belantamab mafodotin, and neurological complications like sixth nerve palsy in the context of multiple myeloma. Additionally, research includes the status of revaccination following bone marrow transplant and CAR T-cell therapy. Sethi's work contributes to understanding the complexities of multiple myeloma treatment and patient management, with a h-index of 4 and 62 total citations across 13 publications.

Metrics

h-index: 4
Publications: 13
Citations: 62

Positions

Assistant Professor publications 2022–2025

University of Arkansas for Medical Sciences Internal Medicine, College of Medicine Institutional directory

Selected Publications

Revaccination status after bone marrow transplant and chimeric antigen receptor T-cell therapy. (2025)

JCO Oncology Practice DOI OpenAlex
Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care (2025)

Cancers 2 citations DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

Cureus 2 citations DOI OpenAlex
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy (2022)

Bone Marrow Transplantation 22 citations DOI OpenAlex
Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy (2022)

Blood 7 citations DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

Blood DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

Blood DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Poster: MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience (2022)

American Journal of Hematology 16 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

Journal of Clinical Medicine 13 citations DOI OpenAlex